Influenza

Veterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.

Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

The federal agency gave the nod to FluMist nasal spray to allows individuals to administer the vaccine themselves and as a caregivers to others.

First case this year without a documented occupational exposure to infected animals.

As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.

Transmission to humans is limited in the US, but concerns linger, especially in the wake of the COVID-19 pandemic.

The companies’ study met 1 of their 2 primary immunogenicity objectives.

Addressing this threat requires the development of effective vaccines and therapeutics specifically targeting evolving H5N1 viruses.

The individuals who worked in an egg layer facility in Colorado were confirmed to have H5N1 and they have reported mild symptoms without hospitalizations.

Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.

Adults 65 and older account for 70–85% of annual influenza-related deaths in the USA, underscoring the need for improved vaccine options, as current injectable vaccines show modest efficacy in many seasons.

The $176 million award is for late-stage development of widespread immunization capability against H5 (avian) influenza, should such vaccines be needed.

The case occurred to a man in Colorado who had direct contact with cattle and state public health officials offer details on the patient as well as the risk to the public.

Recent studies in Emerging Infectious Diseases have highlighted the persistence of highly pathogenic avian influenza A (H5N1) virus on milking equipment surfaces and its presence in dairy cattle mammary glands.

Michigan is taking decisive action to support dairy farms affected by the recent outbreak of highly pathogenic avian influenza (HPAI).

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

This man was the first person globally to have been diagnosed with influenza A(H5N2).

This is the second case in Michigan and it is confirmed in another farmworker who worked with infected cattle.

In a human challenge, an investigational spray, Neumifil (HEX17), manufactured by Pneumagen, reported its results at the recent American Thoracic Society meeting.

A Michigan farmworker who had regular contact with livestock was confirmed to have contracted the virus.

Both the World Health Organization and FDA have now recommended this particular set of viruses be left off influenza vaccines for the 2024-2025 respiratory virus season. A new study points to further evidence of their extinction.

Insights from virologist Erin Sorrell PhD MSc offer perspectives on prevention and response strategies.

A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.